Hypertension

Intensive systolic blood pressure control led to a large absolute difference in death and HF among patients with abnormal biomarker levels of hscTnT and NTproBNP.

Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.

Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.

Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.

Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.

Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.

Dr. Bhatt discusses the growing field of knowledge surrounding icosapent ethyl treatment in cardiovascular care.

Data from the Salt Substitute and Stroke Study suggest switching from regular salt to a salt substitute could reduce the risk of stroke by 14% and investigators believe these results can be applied to patient populations across the world.

Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.

Globally, 331 million women and 317 million men had hypertension in 1990, compared with 626 million women and 652 million men in 2019.

Pictorial data on carotid intima-media thickness and presence of carotid plaques can improve prescription of lipid-lowering drugs.

There was little difference in hospitalization and mortality rates between vaccinated schizophrenia patients and vaccinated control patients.

Data show the change in 24-hour ambulatory systolic blood pressure was significant between treatment and control groups with a reduction of 7.1 mm Hg.

Kelly Chin, MD discusses the recent FDA approval of selexipag IV and breakthroughs in the cardiovascular care space.

A retrospective cohort study with data from nearly 4 million patients with hypertension from the US, Germany, and South Korea found ACEs and ARBs provide similar efficacy for prevention of cardiovascular events, but ACEs were associated with a greater risk of adverse events.

A meta-analysis of 14 studies suggests use of antihypertensive agents known to cross the blood-brain barrier was associated with improved memory recall over time compared to nonpenetrant agents in older adults with hypertension.

Data show HDP occurred in 7.4% of pregnancies in France during the study period.

The AHA has released a scientific statement highlighting the importance of prescribing physical activity as a first-line treatment in patient populations with elevated blood pressure or elevated cholesterol.

New observational data from the SPRINT trial provides further support of using a more intense blood pressure goal, suggesting use of 120 mmHg as a goal rather than 140 mmHg could reduce the risk of major adverse cardiovascular events.

An analysis of patients who achieved blood pressure goal within a digital care program details the potential ability of digital health interventions to improve management of patients with hypertension.

Results of RADIANCE-HTN TRIO suggest ultrasound renal denervation could improve blood pressure control in patients with refractory hypertension, suggesting RDN was associated with a mean reduction of 8 mmHg from baseline a 4.5 mmHg improvement over sham procedure.

There was no significant association between uric acid levels and incident stroke.

A systematic review and meta-analysis of studies examining pediatric type 2 diabetes indicate hypertension or albuminuria was present among approximately 20% of children with type 2 diabetes.

Data from an analysis of NHANES suggest nearly 1-in-5 adults with hypertension were also taking medication that may increase blood pressure.

The USPSTF has released a recommendation statement related to hypertension screenings among adults without known hypertension.